Dreaming and hallucinations - Continuity or discontinuity? Perspectives from dementia with Lewy bodies

Consciousness and Cognition

Volumn 20, Issue 4, 2011, Pages 1016-1020

  Collerton, Daniel ^a   Perry, Elaine ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acetylcholine; Delusions; Dopamine; Dreaming; Hallucinations; PAD model; Serotonin; Visual perception

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; SEROTONIN 2A AGONIST; SEROTONIN AGONIST;

ARTICLE; DEMENTIA; DREAMING; DRUG EFFECT; HUMAN; LEWY BODY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; PHENOMENOLOGY; PSYCHOPHARMACOLOGY; PSYCHOSIS; VISUAL HALLUCINATION;

DREAMS; HALLUCINATIONS; HUMANS; LEWY BODY DISEASE; MODELS, NEUROLOGICAL; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; SLEEP, REM;

EID: 80054857235     PISSN: 10538100     EISSN: 10902376     Source Type: Journal    
DOI: 10.1016/j.concog.2011.03.024     Document Type: Article

References (49)

1. Arnulf I., Bonnet A.M., Damier P., Bejjani B.P., Seilhean D., Derenne J.P., et al. Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis. Neurology 2000, 55:281-288.
2. Ballard C., Piggott M., Johnson M., Cairns N., Perry R., McKeith I., et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology 2000, 48:868-876.
3. Barnes J., Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:190-192.
4. Boeve B.F., Silber M.H., Ferman T.J. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology 2004, 17:146-157.
5. Brown L.J.E., McGrory S., McLaren L., Starr J.M., Deary I.J., MacLullich A.M.J. Cognitive visual perceptual deficits in patients with delirium. Journal of Neurology, Neurosurgery and Psychiatry 2009, 80:594-599.
6. Cheng A.V., Ferrier I.N., Morris C.M., Jabeen S., Sahgal A., McKeith I.G., et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. Journal of Neurological Science 1991, 106:50-55.
7. Christodoulou C., Melville P., Scherl W.F., Macallister W.S., Elkins L.E., Krupp L.B. Effects of donepezil on memory and cognition in multiple sclerosis. Journal of Neurological Science 2006, 245:127-136.
8. Cicogna P.C., Occhionero M., Natale V., Esposito M.J. Bizarreness of size and shape in dream images. Consciousness and Cognition 2007, 16:381-390.
9. Collerton D., Mosimann U.P. Visual hallucinations. Wiley interdisciplinary reviews: Cognitive science 2010, John Wiley and Sons, New Jersey. M. Petersen, L. Nadel (Eds.).
10. Collerton D., Perry E., McKeith I. Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behavioral and Brain Sciences 2005, 28:737-756.
11. Cummings J., Emre M., Aarsland D., Tekin S., Dronamraju N., Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Journal of Alzheimers Disease 2010, February 17. [Epub ahead of print].
12. David R., Koulibaly M., Benoit M., Garcia R., Caci H., Darcourt J., et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases. A SPECT study with partial volume effect correction. Clinical Neurology and Neurosurgery 2008, 110:19-24.
13. De Cock V.C., Vidailhet M., Arnulf I. Sleep disturbances in patients with parkinsonism. Nature Clinical Practice Neurology 2008, 4:254-266.
14. Dooley M., Markham A. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs and Aging 1998, 12:495-514.
15. Dunn N.R., Pearce G.L., Shakir S.A. Adverse effects associated with the use of donepezil in general practice in England. Journal of Psychopharmacology 2000, 14:406-408.
16. ffytche D.H. The visual unconscious. Perspectives from the Charles Bonnet syndrome. New horizons in the neuroscience of consciousness 2010, John Benjamin, Amsterdam. E.K. Perry, D. Collerton, C.H. Ashton, F. LeBeau (Eds.).
17. Gjerstad M.D., Boeve B., Wentzel-Larsen T., Aarsland D., Larsen J.P. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:387-391.
18. Goldman J.G., Goetz C.G., Brandabur M., Sanfilippo M., Stebbins G.T. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Movement Disorders 2008, 23:2248-2250.
19. Graham G., Dean J., Mosimann U.P., Colbourn C., Dudley R., Clarke M., et al. Specific attentional impairments and complex visual hallucinations in eye disease. International Journal of Geriatric Psychiatry 2010, [epub PMID: 20684031].
20. Hobson J.A., Pace-Schott E.F. The cognitive neuroscience of sleep: Neuronal systems, consciousness and learning. Nature Reviews Neuroscience 2002, 3:679-693.
21. Hodoba D., Hrabrić K., Krmpotić P., Brecić P., Kujundzić-Tiljak M., Majdaneić Z. Dream recall after night awakenings from tonic/phasic REM sleep. Collegium Antropologicum 2008, 32(Suppl. 1):69-73.
22. Iranzo A., Santamaria J., Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Medicine Reviews 2009, 13:385-401.
23. Iseki E., Marui W., Nihashi N., Kosaka K. Psychiatric symptoms typical of patients with dementia with Lewy bodies - Similarity to those of levodopa-induced psychosis. Acta Neuropsychiatrica 2002, 14:237-241.
24. Kalia M. Neurobiology of sleep. Metabolism 2006, 55(Suppl. 2):S2-S6.
25. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2005, 65:1863-1872.
26. McKeith I.G., Wesnes K.A., Perry E., Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders 2004, 18:94-100.
27. Monti J.M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Medicine Reviews 2007, 11:113-133.
28. Murillo-Rodríguez E., Arias-Carrión O., Sanguino-Rodríguez K., González-Arias M., Haro R. Mechanisms of sleep-wake cycle modulation. CNS and Neurological Disorders Drug Targets 2009, 8:245-253.
29. Ohayon M.M. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Research 2000, 97:153-164.
30. Ohayon M.M., Priest R.G., Caulet M., Guilleminault C. Hypnagogic and hypnopompic hallucinations: Pathological phenomena?. British Journal of Psychiatry 1996, 169:459-467.
31. Ozer F., Merai H., Hanoglu L., et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. Journal of Clinical Neuroscience 2007, 14:742-746.
32. Pace-Schott E.F., Gersh T., Silvestri R., Stickgold R., Salzman C., Hobson J.A. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. Journal of Sleep Research 2001, 10(2):129-142.
33. Papapetropoulos S., Mash D.C. The neurochemical mechanism of rebound psychosis in Parkinson's disease. Movement Disorders 2005, 20:515.
34. Perry, E.K. (2002). Plants of the gods: Ethnic routes to altered consciousness. In K. Elaine Perry, Heather Ashton, Allan H. Young (Eds.), Neurochemistry of consciousness: Neurotransmitters in mind (advances in consciousness research).
35. Perry E.K., Marshall E., Kerwin J., Smith C.J., Jabeen S., Cheng A.V., et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. Journal of Neurochemistry 1990, 55:1454-1456.
36. Perry E.K., Marshall E., Thompson P., McKeith I.G., Collerton D., Fairbairn A.F., et al. Monoaminergic activities in Lewy body dementia: Relation to hallucinosis and extrapyramidal features. Journal of Neural Transmission 1993, 6:167-177.
37. Perry E.K., McKeith I., Thompson P., Marshall E., Kerwin J., Jabeen S., et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Annals of the New York Academy of Sciences 1991, 640:197-202.
38. Pimlott S.L., Piggott M., Ballard C., McKeith I., Perry R., Kometa S., et al. Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiological Disorders 2006, 21:50-56.
39. Ramirez-Ruiz B., Junque C., Marti M.J., et al. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Movement Disorders 2006, 21:1483-1487.
40. Roselli F., Pisciotta N.M., Perneczky R., Pennelli M., Aniello M.S., De Caro M.F., et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FP-CIT SPECT study. Movement Disorders 2009, 24:2097-2103.
41. Schwartz S., Maquet P. Sleep imaging and the neuropsychological assessment of dreams. Trends in Cognitive Sciences 2002, 6:23-30.
42. Sharf B., Moskovitz C., Lupton M.D., Klawans H.L. Dream phenomena induced by chronic levodopa therapy. Journal of Neural Transmission 1978, 43:143-151.
43. Siegel J.M. The neurobiology of sleep. Seminars in Neurology 2009, 29:277-296.
44. Sinforiani E., Pacchetti C., Zangaglia R., Pasotti C., Manni R., Nappi G. REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A two-year follow up. Movement Disorders 2008, 23:1441-1445.
45. Stahl S.M., Markowitz J.S., Papadopoulos G., Sadik K. Examination of night time sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research Opinion 2004, 20:517-524.
46. Teaktong T., Piggott M.A., Mckeith I.G., Perry R.H., Ballard C.G., Perry E.K. Muscarinic M2 and M4 receptors in anterior cingulate cortex: Relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behavioural Brain Research 2005, 161:299-305.
47. Toscano A., Pancaro C., Peduto V.A. Scopolamine prevents dreams during general anesthesia. Anesthesiology 2007, 106:952-955.
48. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
49. Zahodne L.B., Fernandez H.H. Pathophysiology and treatment of psychosis in Parkinson's disease: A review. Drugs and Aging 2008, 25:665-682.